Mineralys Therapeutics (MLYS) Change in Cash (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Change in Cash data on file, last reported at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 218.12% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$52.2 million (down 170.02% YoY), and the FY2025 full-year result was $58.8 million, down 9.19% from the prior year.
• Change in Cash eased to -$60.1 million in Q1 2026, from -$44.7 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $115.8 million in Q3 2025 to a low of -$79.3 million in Q3 2022.
• A 5-year average of $6.0 million and a median of $5.4 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash surged 832.74% in 2023 and tumbled 365.66% in 2025, its largest moves.
• Tracing MLYS's Change in Cash over 5 years: stood at $38.7 million in 2022, then slumped by 195.48% to -$37.0 million in 2023, then surged by 145.46% to $16.8 million in 2024, then plunged by 365.66% to -$44.7 million in 2025, then tumbled by 34.62% to -$60.1 million in 2026.
• Business Quant data shows MLYS's Change in Cash at -$60.1 million in Q1 2026, -$44.7 million in Q4 2025, and $115.8 million in Q3 2025.